Abstract library

18 results for "Castro-Rivera".
#2301 Trends in Management of Gastro-Intestinal Neuroendocrine Tumors in Inflammatory Bowel Diseases: The Contribute of a Case Series.
Introduction: The risk to develop gastro-intestinal malignancies is higher in patients affected by inflammatory bowel diseases (IBD). Apart from colo-rectal cancer, related to a long standing inflammation, there is a growing evidence of neuroendocrine tumors (NETs) in these patients and a correlation between these two diseases has been postulated. We report four cases of NETs in IBD.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Doctor Stefano Rizza
#1252 Radio-chemotherapy versus Surgery in Non-metastatic Ano-rectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues
Introduction: Neuroendocrine carcinomas (NEC) of the anus or the rectum are a rare disease, accounting for less than 1% of all digestive malignancies. Most are metastatic at diagnosis and treated with a platinum-based chemotherapy. No guidelines for localized tumors exist.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Bertrand Brieau
#1725 Safety of Lanreotide 120 mg ATG (LAN) in Combination with Metformin (MET) in Patients (pts) with Progressive Advanced Well-Differentiated (WD) Gastro-Intestinal (GI) or Lung Carcinoids. A Pilot, One-Arm, Open-Label, Prospective Study: The MetNET-2 Trial
Introduction: Anti proliferative effect of LAN ATG 120 mg has been investigated in 204 GI-NET pts in Clarinet study with a 53% reduction in risk of death/progression vs placebo. An increasing number of trials have associated MET with better outcome in cancer pts due to a reduction of insulin/IGF1 levels and modulation of AMPK and TSC1-2/mTOR. The retrospective PRIME-net study conducted on 445 Italian pts, suggest that addition of MET to everolimus and/or SSA provides clinical benefit in diabetic pancreatic NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Sara Pusceddu
Authors: Prinzi N, Femia D, Concas L, Lo Russo G, ...
Keywords: lanreotide, metformin
#1888 Selective Transarterial Embolization of Gastro-Entero Pancreatic (GEP) Neuroendocrine Tumors (NET) with Advanced Locoregional Disease and/or Liver Metastases
Introduction: Selective transarterial embolization(TAE) and chemoembolization(TACE),are alternative options to systemic therapies in patients with GEP-NET G1/G2 with advanced locoregional disease and/or unresectable liver metastases
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Concepcion Blanco
Keywords: TACE, TAE, GEP-NET
#25 Predictors of response to radio-embolization (TheraSphere ®) treatment of neuro-endocrine liver metastasis
Introduction: Neuroendocrine tumors (NET) frequently metastasize to the liver. Most patients have diffuse, and therefore incurable, disease. NET liver metastasis has been shown to respond to yttrium-90 microspheres therapy. This study aims to define factors that predict response to radio-embolization in patients with NET liver metastases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Mazen Hassanain
#788 A Novel Animal Model for Medullary Thyroid Carcinoma
Introduction: Medullary thyroid carcinoma (MTC) is a neuroendocrine cancer originating from calcitonin-producing C-cells. Surgical resection is the most effective treatment currently available. Understanding the molecular pathways mediating MTC is crucial for the development of novel therapies. Cyclin-dependent kinase 5 (Cdk5) and its activators, p35 and p25, have recently been implicated in MTC etiology. P25 is a cleavage product of p35 and the binding of p25 to Cdk5 leads to aberrant Cdk5 activity.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Karine Pozo
Authors: Pozo K, Castro-Rivera E, Tan C, Siegl V, ...
Keywords: thyroid, Cdk5
#2147 Nutritional Assessment and Vitamin Deficiencies in Patients with NETs
Introduction: As a result of disease or related to its management, patients with neuroendocrine tumours may have altered gut or pancreatic function that can cause nutritional deficiencies.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Mark Reynolds
Authors: Lim S, Reynolds M, Rees D A, Chaudhry R, ...
#358 Enhanced Combined 177Lu-DOTATATE and 90Y-DOTATATE Treatment of Patients with Metastatic Neuroendocrine Tumors Refractory to Conventional Therapy: An Ongoing Study.
Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of ß-emitting radioisotopes have been reported.
Conference:
Category: Basic
Presenting Author: Dr Andrew Mallia
#380 Diagnosis and Management of Insulinomas in a Tertiary Referral Center: A 10-Year Review
Introduction: Insulinomas are rare tumors. There are few reports of insulinoma from India. We present a retrospective analysis of patients with insulinoma evaluated at a tertiary referral center in South India.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Vijay Ramachandran
#972 Anti-Tumor Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to Ki-67 Score: A Multicentric Study From ELIOS (Educational Learning Investigational Observational Study)
Introduction: SSAs have been demonstrated to have antiproliferative effects in ileal NETs. The 2010 WHO NET classification provides a grading score which can be helpful in predicting tumor response to SSA.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Antongiulio Faggiano
Keywords: NET, SSA, G1, G2, WHO classification